Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Tick Bites D064927 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Reproductive Tract Infections D060737 1 associated lipids
Granulomatous Mastitis D058890 1 associated lipids
Trichiasis D058457 1 associated lipids
Asymptomatic Infections D058345 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neglected Diseases D058069 3 associated lipids
Corneal Endothelial Cell Loss D055954 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Acute Lung Injury D055371 33 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Tracheobronchomalacia D055089 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Hyper-IgM Immunodeficiency Syndrome D053306 1 associated lipids
Pyomyositis D052880 2 associated lipids
Male Urogenital Diseases D052801 1 associated lipids
Tendinopathy D052256 3 associated lipids
Mucositis D052016 7 associated lipids
Pyloric Stenosis, Hypertrophic D046248 2 associated lipids
Moraxellaceae Infections D045828 3 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Communicable Diseases, Emerging D021821 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Pouchitis D019449 3 associated lipids
Pseudolymphoma D019310 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Abdominal Abscess D018784 2 associated lipids
Parasitemia D018512 5 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
T-Lymphocytopenia, Idiopathic CD4-Positive D018344 1 associated lipids
Furcation Defects D017823 1 associated lipids
Granuloma, Pyogenic D017789 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Pelvic Pain D017699 7 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Neisseriaceae Infections D016870 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Pneumocystis Infections D016720 1 associated lipids
Vaginosis, Bacterial D016585 10 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Erythema Chronicum Migrans D015787 3 associated lipids
Corneal Edema D015715 3 associated lipids
Frontal Sinusitis D015522 1 associated lipids
Ethmoid Sinusitis D015521 2 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Superinfection D015163 3 associated lipids
Yaws D015001 4 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Vomiting D014839 21 associated lipids
Vertigo D014717 4 associated lipids
Urticaria D014581 13 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Urethral Diseases D014522 4 associated lipids
Typhus, Endemic Flea-Borne D014437 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Urogenital D014401 2 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Trismus D014313 1 associated lipids
Trichomonas Infections D014245 3 associated lipids
Toxoplasmosis, Ocular D014126 2 associated lipids
Toxoplasmosis, Congenital D014125 2 associated lipids
Toxoplasmosis D014123 9 associated lipids
Tooth, Impacted D014095 9 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Erosion D014077 2 associated lipids
Tick Infestations D013984 4 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis, Latent D013592 4 associated lipids
Syphilis D013587 6 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Diseases D013272 7 associated lipids
Stevens-Johnson Syndrome D013262 3 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Desnica B et al. Myalgia and swelling of interphalangeal joints as side-effect of prolonged azithromycin therapy in patient with pelvic actinomycosis: case report. 2007 Scand. J. Infect. Dis. pmid:17366044
Dakdouki GK et al. Azithromycin-induced rash in infectious mononucleosis. 2002 Scand. J. Infect. Dis. pmid:12587634
Batieha A et al. No advantage of treating acute respiratory tract infections with azithromycin in a placebo-controlled study. 2002 Scand. J. Infect. Dis. pmid:12064684
Schönwald S et al. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. 1994 Scand. J. Infect. Dis. pmid:7747094
Brandén E et al. Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection. 2004 Scand. J. Infect. Dis. pmid:15764166
Dickerson FB et al. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. 2009 Schizophr. Res. pmid:19464853
Feary DJ et al. Lawsonia intracellularis proliferative enteropathy in a foal. 2007 Schweiz. Arch. Tierheilkd. pmid:17410971
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Gensel JC et al. Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment. 2017 Sci Rep pmid:28057928
Wang A et al. Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia. 2016 Sci Rep pmid:27405358
Menzel M et al. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. 2016 Sci Rep pmid:27350308
Zeng J et al. Mechanism of azithromycin inhibition of HSL synthesis in Pseudomonas aeruginosa. 2016 Sci Rep pmid:27075730
Pansieri C et al. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey. 2014 Sci Rep pmid:24518104
Das MC et al. Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: A combinatorial study with azithromycin and gentamicin. 2016 Sci Rep pmid:27000525
Gualdoni GA et al. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. 2015 Sci Rep pmid:26152605
Friesen J et al. Natural immunization against malaria: causal prophylaxis with antibiotics. 2010 Sci Transl Med pmid:20630856
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Sidhu H et al. Risk assessment of biosolids-borne ciprofloxacin and azithromycin. 2019 Sci. Total Environ. pmid:30463165
Sidhu H et al. Plant toxicity and accumulation of biosolids-borne ciprofloxacin and azithromycin. 2019 Sci. Total Environ. pmid:30340267
Sidhu H et al. Retention-release of ciprofloxacin and azithromycin in biosolids and biosolids-amended soils. 2019 Sci. Total Environ. pmid:30196217
Sidhu H et al. Bioavailability of biosolids-borne ciprofloxacin and azithromycin to terrestrial organisms: Microbial toxicity and earthworm responses. 2019 Sci. Total Environ. pmid:30195128
Wawer MJ et al. AIDS intervention in Uganda. 1995 Science pmid:7570005
Seguí Díaz M [What is the best treatment for urogenital Chlamydia trachomatis infection?] Semergen pmid:27068255
Berger BW Lyme disease. 1993 Semin Dermatol pmid:8312152
Pedro-Botet ML and Sabrià M Legionellosis. 2005 Semin Respir Crit Care Med pmid:16388431
Suriawinata A and Min AD A 33-year-old woman with jaundice after azithromycin use. 2002 Semin. Liver Dis. pmid:12016551
Weinstein SA and Stiles BG A review of the epidemiology, diagnosis and evidence-based management of Mycoplasma genitalium. 2011 Sex Health pmid:21592428
McCormick DF et al. Prevention and control of sexually transmissible infections among hotel-based female sex workers in Dhaka, Bangladesh. 2013 Sex Health pmid:24262217
Robertson A et al. Case report: lymphogranuloma venereum in New Zealand. 2008 Sex Health pmid:19061558
Stratov I et al. Azithromycin: more lethal than chloramphenicol? 2013 Sex Health pmid:23448962
Renault CA et al. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. 2011 Sex Health pmid:21371385
Jones S et al. The tip of the iceberg: opportunistic screening for Chlamydia trachomatis in asymptomatic patients attending a young people's health clinic reveals a high prevalence--a pilot study. 2004 Sex Health pmid:16334993
Grimes M et al. Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington. 2012 Sex Transm Dis pmid:23191949
Zheng H et al. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. 2015 Sex Transm Dis pmid:25668641
Muldoon EG et al. Treponema pallidum azithromycin resistance in Dublin, Ireland. 2012 Sex Transm Dis pmid:23001265
Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. 2012 Sex Transm Dis pmid:23001267
Starnino S et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. 2012 Sex Transm Dis pmid:23001269
Handsfield HH et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. 1994 Mar-Apr Sex Transm Dis pmid:9071422
Asbel LE et al. School-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae among Philadelphia public high school students. 2006 Sex Transm Dis pmid:16614587
Howell MR et al. Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. 1999 Sex Transm Dis pmid:10534206
Chen S et al. Universal screening or prophylactic treatment for Chlamydia trachomatis infection among women seeking induced abortions: which strategy is more cost-effective? 2007 Sex Transm Dis pmid:17414068
Lavoué V et al. Screening for Chlamydia trachomatis using self-collected vaginal swabs at a public pregnancy termination clinic in France: results of a screen-and-treat policy. 2012 Sex Transm Dis pmid:22801345
Bornstein M et al. Factors Associated With Primary Care Physician Knowledge of the Recommended Regimen for Treating Gonorrhea. 2017 Sex Transm Dis pmid:27898574
Carlin EM and Barton SE Azithromycin as a cost-effective treatment for nongonococcal urethritis in men. 1997 Sex Transm Dis pmid:9018784
Peters RP et al. Gonococcal Conjunctivitis Despite Successful Treatment of Male Urethritis Syndrome. 2016 Sex Transm Dis pmid:26760182
Gratrix J et al. A Retrospective Review of Treatment Failures Using Azithromycin and Doxycycline in the Treatment of Rectal Chlamydia Infections in Women and Men Who Have Sex With Men. 2016 Sex Transm Dis pmid:26760180
Boix V et al. Polyostotic osteitis in secondary syphilis in an HIV-infected patient. 2013 Sex Transm Dis pmid:23859912
Hillis SD et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. 1998 Sex Transm Dis pmid:9437777
Singh AE et al. Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian Sexually Transmitted Infection Clinics, 2010-2013. 2015 Sex Transm Dis pmid:25970311
Stamm WE et al. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. 2007 Sex Transm Dis pmid:17297383